Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 451-458

  Rekhtman, Natasha ^a   Brandt, Suzanne M ^a   Sigel, Carlie S ^a   Friedlander, Maria A ^a   Riely, Gregory J ^a   Travis, William D ^a   Zakowski, Maureen F ^a   Moreira, Andre L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Cytology; EGFR; KRAS; Non small cell carcinoma; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL PRACTICE; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THORAX;

EID: 79951769998     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820517a3     Document Type: Article

References (54)

1. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
2. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21(Suppl 2):S16-S22. (Pubitemid 351592769)
3. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
4. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
6. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
7. West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009;136:1112-1118.
8. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In VT DeVita, S Hellman, SA Rosenberg (Eds.), Cancer: Principles and Practices of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005. Pp. 753-810.
9. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123:115S-128S. (Pubitemid 36135709)
10. Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:3-8. (Pubitemid 36254670)
11. Fitzgibbons PL, Kern WH. Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases. Hum Pathol 1985;16:463-466. (Pubitemid 15072545)
12. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537-540. (Pubitemid 30432112)
13. Thomas JS, Lamb D, Ashcroft T, et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 1993;48:1135-1139. (Pubitemid 23336832)
14. Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype nonsmall- cell lung cancer. J Clin Oncol 2009;27:e141- e142; author reply e143-e144.
15. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009;17:206-218.
16. Loo PS, Tomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
17. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
18. Yazdi HM, MacDonald LL, Hickey NM. Thoracic fine needle aspiration biopsy versus fine needle cutting biopsy. A comparative study of 40 patients. Acta Cytol 1988;32:635-640.
19. Zusman-Harach SB, Harach HR, Gibbs AR. Cytological features of non-small cell carcinomas of the lung in fine needle aspirates. J Clin Pathol 1991;44:997-1002.
20. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.). Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
21. Ang DC, Ghaffar H, Zakowski MF, et al. Expression of squamous markers in lung adenocarcinoma: clinicopathologic and molecular correlates, and implications for differentiation from squamous cell carcinoma. Modern Pathol 2010;23:1770a.
22. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72.
23. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
24. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
25. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010;134:1628-1638.
26. Truong LD, Underwood RD, Greenberg SD, et al. Diagnosis and typing of lung carcinomas by cytopathologic methods. A review of 108 cases. Acta Cytol 1985;29:379-384. (Pubitemid 15044829)
27. Suprun H, Pedio G, Ruttner JR. The diagnostic reliability of cytologic typing in primary lung cancer with a review of the literature. Acta Cytol 1980;24:494-500. (Pubitemid 11253603)
28. Kamiya M, Uei Y, Shimosato Y. Cytologic features of peripheral squamous cell carcinoma of the lung. Acta Cytol 1995;39:61-68.
29. Tanaka T, Yamamoto M, Tamura T, et al. Cytologic and histologic correlation in primary lung cancer. A study of 154 cases with resectable tumors. Acta Cytol 1985;29:49-56. (Pubitemid 15174457)
30. Yilmaz A, Uskul TB, Bayramgurler B, et al. Cell type accuracy of transthoracic fine needle aspiration material in primary lung cancer. Respirology 2001;6:91-94. (Pubitemid 32666826)
31. Travis WD, Brambilla E, Noguchi M, et al. The New IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma Classification. J Thoracic Oncol In press.
32. Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978;9:143-156. (Pubitemid 8385141)
33. Yesner R. Large cell carcinoma of the lung. Semin Diagn Pathol 1985;2:255-269. (Pubitemid 16249166)
34. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 2009;17:383-392.
35. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
36. Vazquez MF, Koizumi JH, Henschke CI, et al. Reliability of cytologic diagnosis of early lung cancer. Cancer 2007;111:252-258. (Pubitemid 47301284)
37. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009;4:1202-1211.
38. Barbazza R, Toniolo L, Pinarello A, et al. Accuracy of bronchial aspiration cytology in typing operable (stage I-II) pulmonary carcinomas. Diagn Cytopathol 1992;8:3-7.
39. Erozan YS, Frost JK. Cytopathologic diagnosis of lung cancer. Semin ncol 1974;1:191-198.
40. Foot NC. The identification of types of pulmonary cancer in cytologic smears. Am J Pathol 1952;28:963-983.
41. Foot NC. The value of exfoliative cytology to the general practitioner. N Engl J Med 1953;249:557-561.
42. Kirsh MM, Orvald T, Naylor B, et al. Diagnostic accuracy of exfoliative pulmonary cytology. Ann Thorac Surg 1970;9:335-338.
43. Pilotti S, Rilke F, Gribaudi G, et al. Transthoracic fine needle aspiration biopsy in pulmonary lesions. Updated results. Acta Cytol 1984;28:225-232. (Pubitemid 14110564)
44. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-619.
45. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
46. Santambrogio L, Nosotti M, Bellaviti N, et al. CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: a prospective, randomized study of immediate cytologic evaluation. Chest 1997;112:423-425. (Pubitemid 27349433)
47. Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. Diagn Cytopathol 2002;27:1-4. (Pubitemid 34721605)
48. Bibbo M, Fennessy JJ, Lu CT, et al. Bronchial brushing technique for the cytologic diagnosis of peripheral lung lesions. A review of 693 cases. Acta Cytol 1973;17:245-251.
49. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-2037.
50. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to egfr inhibitors and enhanced detection of the T790M mutation using a Locked Nucleic Acid-Based Assay. Clin Cancer Res In press.
51. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007;2:1086-1090. (Pubitemid 350307900)
52. Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007;131:1628-1634. (Pubitemid 46981613)
53. Zakowski MF, Ladanyi M, Rekhtman N, et al. Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: the Memorial Sloan- Kettering experience. J Clin Oncol 2008;26:22031.
54. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-994. (Pubitemid 351398092)